About Us

Garage Brain Science (GBS)
博士.jpg

GBS is a biotechnology company focused on proteopathy—diseases driven by abnormal protein folding, condensation, and aggregation.
Our mission is to enable earlier, actionable management of protein-misfolding disorders across neurodegeneration (e.g., ALS, Parkinson’s) and metabolic disease, including diabetes.

Disease Origin™ Platform

Integrating biofluid protein signals with LLPS-informed pathway analysis to detect and stratify early pathophysiological risk.

Reprofold® Technology

An investigational approach designed to help restore proteostasis and cellular function through targeted intervention.
Together with global clinical partners, GBS is advancing a pre-symptomatic care model built on longitudinal monitoring.
Advancing the Future of Proteostasis

Company Milestones

Deeply rooted in academic research and clinical translation, continuously advancing the frontiers of medicine.
2012
 
Published research in Nature Communications revealing the prion-like properties of the disease-associated protein TDP-43.
2013
 
Published research in Nature Communications identifying the first drug targeting liquid-liquid phase separation (LLPS).
2014
 
Awarded the 8th Alzheimer's Drug Discovery Foundation (ADDF) Young Investigator Award.
2017
 
International Collaboration: Initiated a partnership with laboratories at the French National Institute of Health and Medical Research (Inserm).
2020
 
US Partnership: Collaborative partner of the National Institutes of Health (NIH).
Academic Collaboration: Research partnership with UC Santa Barbara (UCSB).
Local Collaboration: Partnered with National Taiwan University Hospital (NTUH).
2021
 
Achieved Proof of Concept (PoC) for the NeuroGuard Plasma Test in blood-based detection.
Discovered novel blood biomarkers for ALS, AD, and PD.
2022
 
Product & Clinical Progress: Completed NeuroGuard Plasma Test development and achieved PoC for PreciseOligo Dx.
  • Identified biomarkers for the "presymptomatic phase" of neurodegenerative diseases.
  • Initiated pilot clinical trial for Reprofold®.
  • Established operations at Central Taiwan Innovation Campus (CTIC).
2023
 
Established US subsidiary in California. Demonstrated efficacy of Reprofold® (Published in Scientific Reports).
2024
 
Completed clinical validation of eHIMP blood test (Published in Brain). Validated novel biomarkers for neurodegeneration and pre-diabetes.
2025
 
Clinical validation of the Disease Origin™ AI Platform. Completed prototype validation for neurodegeneration and pre-diabetes rapid tests.
TOP